Back to top
more

Personalis (PSNL)

(Delayed Data from NSDQ)

$1.25 USD

1.25
147,226

-0.05 (-3.85%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $1.24 -0.01 (-0.80%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (159 out of 251)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for PSNL

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Personalis, Inc. [PSNL]

Reports for Purchase

Showing records 1 - 20 ( 22 total )

Company: Personalis, Inc.

Industry: Medical - Generic Drugs

Record: 1

02/29/2024

Company Report

Pages: 7

Robust Demand for NeXT Personal Dx; Multiple Data Readouts in Mid-2024; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Personalis, Inc.

Industry: Medical - Generic Drugs

Record: 2

11/08/2023

Company Report

Pages: 7

Clinical Updates of NeXT Personal Could Support Reimbursement Submission; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: Personalis, Inc.

Industry: Medical - Generic Drugs

Record: 3

10/25/2023

Daily Note

Pages: 4

NeXT Personal Gained Proof-of-Concept in Early Lung Cancer; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 5.00

Research Provided by a Third Party

Company: Personalis, Inc.

Industry: Medical - Generic Drugs

Record: 4

08/09/2023

Company Report

Pages: 7

Collaborations to Aid in Diagnostic Business Growth; New PT $7.50; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: Personalis, Inc.

Industry: Medical - Generic Drugs

Record: 5

05/04/2023

Company Report

Pages: 6

NeXT Personal Portfolio Progress Continues; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: Personalis, Inc.

Industry: Medical - Generic Drugs

Record: 6

02/24/2023

Company Report

Pages: 7

Expect Slow Growth in Biopharma Business; Lower PT to $10; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: Personalis, Inc.

Industry: Medical - Generic Drugs

Record: 7

01/09/2023

Daily Note

Pages: 3

Diagnostics Business Key for 2023; Aaron Tachibana as Interim CEO to Provide Needed Continuity; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 5.00

Research Provided by a Third Party

Company: Personalis, Inc.

Industry: Medical - Generic Drugs

Record: 8

11/03/2022

Company Report

Pages: 7

Near-Term Headwind to Biopharma Business; Lower PT to $13; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: Personalis, Inc.

Industry: Medical - Generic Drugs

Record: 9

08/04/2022

Company Report

Pages: 7

Biopharma Momentum Continues; Eyes on Clinical Diagnostics, Lower PT $26; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: Personalis, Inc.

Industry: Medical - Generic Drugs

Record: 10

05/05/2022

Company Report

Pages: 7

Expect Return to Growth in 2H22 Despite Headwinds; Lower PT to $30; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: Personalis, Inc.

Industry: Medical - Generic Drugs

Record: 11

02/25/2022

Company Report

Pages: 7

Biopharma Continues to Deliver; VA MVP to Back-Burner; Lower PT to $38; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: Personalis, Inc.

Industry: Medical - Generic Drugs

Record: 12

11/08/2021

Company Report

Pages: 7

Biopharma to drive growth in 2022; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: Personalis, Inc.

Industry: Medical - Generic Drugs

Record: 13

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for PSNL

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Personalis, Inc.

Industry: Medical - Generic Drugs

Record: 14

09/23/2021

Company Report

Pages: 7

Hiccup in Population Sequencing Business Likely Transitory; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Personalis, Inc.

Industry: Medical - Generic Drugs

Record: 15

08/05/2021

Company Report

Pages: 7

Expect Biopharma Business to Bloom; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Personalis, Inc.

Industry: Medical - Generic Drugs

Record: 16

05/06/2021

Company Report

Pages: 7

Strong Growth Momentum Continues; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Personalis, Inc.

Industry: Medical - Generic Drugs

Record: 17

03/31/2021

Daily Note

Pages: 4

Opportunity in Companion Diagnostics; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Company: Personalis, Inc.

Industry: Medical - Generic Drugs

Record: 18

02/26/2021

Company Report

Pages: 7

Expect Growth Momentum to Continue; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Personalis, Inc.

Industry: Medical - Generic Drugs

Record: 19

01/13/2021

Company Report

Pages: 7

Broader Adoption of NeXT Bodes Well for 2021 and Beyond; Higher $50 PT; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Personalis, Inc.

Industry: Medical - Generic Drugs

Record: 20

11/09/2020

Company Report

Pages: 7

Growth Momentum Building up With NeXT Adoption; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party